Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive type of solid tumor that is becoming more common. cis-[PtCl2 (NH3)2] (in short cisplatin or CDDP) has been shown to be effective in treating various cancers, including PDAC. However, the development of resistance to chemotherapy drugs ha...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Bioinorganic Chemistry and Applications |
| Online Access: | http://dx.doi.org/10.1155/bca/5588491 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582276136828928 |
|---|---|
| author | Erika Stefàno Gianluca Rovito Luca G. Cossa Federica De Castro Viviana Vergaro Asjad Ali Giulia My Danilo Migoni Antonella Muscella Santo Marsigliante Michele Benedetti Francesco Paolo Fanizzi |
| author_facet | Erika Stefàno Gianluca Rovito Luca G. Cossa Federica De Castro Viviana Vergaro Asjad Ali Giulia My Danilo Migoni Antonella Muscella Santo Marsigliante Michele Benedetti Francesco Paolo Fanizzi |
| author_sort | Erika Stefàno |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive type of solid tumor that is becoming more common. cis-[PtCl2 (NH3)2] (in short cisplatin or CDDP) has been shown to be effective in treating various cancers, including PDAC. However, the development of resistance to chemotherapy drugs has created a need for the synthesis of new anticancer agents. Platinum-based drugs containing the bidentate ligand phenanthroline have been found to have strong antitumor activity due to their ability to cause DNA damage. In this study, we examined the ability of two Pt (II) cationic complexes, [Pt(η1-C2H4OR) (DMSO) (phen)]+ (in short Pt-EtORSOphen; R = Me, 1; Et, 2), to inhibit the growth and spread of BxPC-3 PDAC cells, in comparison to CDDP. The length of the alkyl chain and its associated lipophilic properties did not affect the anticancer effects of complexes 1 and 2 in BxPC-3 cells. However, it did appear to influence the rapid loss of mitochondrial membrane potential (ΔΨM), suggesting that these complexes could potentially be used as mitochondria-targeted lipophilic cations in anticancer therapy. |
| format | Article |
| id | doaj-art-eed5e916fb2446f79504633e4cd31457 |
| institution | Kabale University |
| issn | 1687-479X |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Bioinorganic Chemistry and Applications |
| spelling | doaj-art-eed5e916fb2446f79504633e4cd314572025-01-30T05:00:04ZengWileyBioinorganic Chemistry and Applications1687-479X2024-01-01202410.1155/bca/5588491Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma CellsErika Stefàno0Gianluca Rovito1Luca G. Cossa2Federica De Castro3Viviana Vergaro4Asjad Ali5Giulia My6Danilo Migoni7Antonella Muscella8Santo Marsigliante9Michele Benedetti10Francesco Paolo Fanizzi11Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Experimental MedicineDepartment of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Department of Biological and Environmental Sciences and Technologies (DiSTeBA)Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive type of solid tumor that is becoming more common. cis-[PtCl2 (NH3)2] (in short cisplatin or CDDP) has been shown to be effective in treating various cancers, including PDAC. However, the development of resistance to chemotherapy drugs has created a need for the synthesis of new anticancer agents. Platinum-based drugs containing the bidentate ligand phenanthroline have been found to have strong antitumor activity due to their ability to cause DNA damage. In this study, we examined the ability of two Pt (II) cationic complexes, [Pt(η1-C2H4OR) (DMSO) (phen)]+ (in short Pt-EtORSOphen; R = Me, 1; Et, 2), to inhibit the growth and spread of BxPC-3 PDAC cells, in comparison to CDDP. The length of the alkyl chain and its associated lipophilic properties did not affect the anticancer effects of complexes 1 and 2 in BxPC-3 cells. However, it did appear to influence the rapid loss of mitochondrial membrane potential (ΔΨM), suggesting that these complexes could potentially be used as mitochondria-targeted lipophilic cations in anticancer therapy.http://dx.doi.org/10.1155/bca/5588491 |
| spellingShingle | Erika Stefàno Gianluca Rovito Luca G. Cossa Federica De Castro Viviana Vergaro Asjad Ali Giulia My Danilo Migoni Antonella Muscella Santo Marsigliante Michele Benedetti Francesco Paolo Fanizzi Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells Bioinorganic Chemistry and Applications |
| title | Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells |
| title_full | Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells |
| title_fullStr | Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells |
| title_full_unstemmed | Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells |
| title_short | Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells |
| title_sort | novel pt ii complexes with anticancer activity against pancreatic ductal adenocarcinoma cells |
| url | http://dx.doi.org/10.1155/bca/5588491 |
| work_keys_str_mv | AT erikastefano novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT gianlucarovito novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT lucagcossa novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT federicadecastro novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT vivianavergaro novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT asjadali novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT giuliamy novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT danilomigoni novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT antonellamuscella novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT santomarsigliante novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT michelebenedetti novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells AT francescopaolofanizzi novelptiicomplexeswithanticanceractivityagainstpancreaticductaladenocarcinomacells |